SCHEMBL17560571

SCHEMBL17560571

CC(C)(C)OC(=O)N=C(NC(=O)OC(C)(C)C)Nc1cc(N)ccc1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.35
AAK1 Q2M2I8 4/20 0.34
KDR P35968 3/20 0.34
TEK Q02763 1/20 0.34
MAPT P10636 3/20 0.34
GAA P10253 1/20 0.34
MAPK1 P28482 1/20 0.34
BRAF P15056 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
PDGFRB P09619 1/20 0.33
MAP4K4 O95819 1/20 0.33
POLB P06746 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GALK1 P51570 1/20 0.32
KMT2A Q03164 1/20 0.32
LMNA P02545 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17560570 1.00 CYP17A1 (0.35) CYP17A1AAK1KDRTEKMAPT
SCHEMBL17570187 1.00 CYP17A1 (0.35) CYP17A1AAK1KDRTEKMAPT
SCHEMBL17569803 0.83 ALDH1A1 (0.52) MAPTGAAMAPK1POLBSMN1; SMN2
SCHEMBL17560521 0.83 ALDH1A1 (0.52) MAPTGAAMAPK1POLBSMN1; SMN2
SCHEMBL17560520 0.83 ALDH1A1 (0.52) MAPTGAAMAPK1POLBSMN1; SMN2
SCHEMBL2231205 0.83 CYP17A1 (0.44) CYP17A1AAK1KDRTEKMAPT
SCHEMBL19271239 0.83 MAPT (0.37) CYP17A1KDRTEKMAPTGAA
SCHEMBL17560616 0.82 MAP4K4 (0.36) CYP17A1AAK1GAANR1H4MAP4K4
SCHEMBL22238138 0.82 HDAC1 (0.41) AAK1SMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL17560615 0.82 MAP4K4 (0.36) CYP17A1AAK1GAANR1H4MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9944641-B2 Isoquinolinone derivatives useful in the treatment of cancer PIERRE FABRE MEDICAMENT (FR) 2018-04-17 US disclosed
US-20170240544-A1 ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER PIERRE FABRE MEDICAMENT (FR) 2017-08-24 US disclosed
EP-3189051-A1 ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER Pierre Fabre Médicament (FR) 2017-07-12 EP disclosed
WO-2016034642-A1 ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER PIERRE FABRE MEDICAMENT (FR) 2016-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170240544-A1 ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER TP53, KRAS, AQP1 CYP17A1 424/4885AAK1 3183/4885KDR 3797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.